Synthesis and characterization of a new Carbon-11 labeled positron emission tomography radiotracer for RIPK1 neuroimaging
Authors:
- Hua ChengHCHua Cheng
- Yongle WangYWYongle Wang
- Yanli WangYWYanli Wang
- Tewodros M. DagnewTDTewodros M. Dagnew
- Anne SiewkoASAnne Siewko
- Breanna Lizeth VarelaBVBreanna Lizeth Varela
- Pengcheng MaPMPengcheng Ma
- Madelyn Rose HalliseyMHMadelyn Rose Hallisey
- Aiping ChengACAiping Cheng
- Changning WangCWChangning Wang
- Yulong XuYXYulong Xu
- 8 May 2025
- journal article
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 192 (Pt B) , 110324
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Application of advanced biosensors in nervous system diseasesInterdisciplinary Medicine, 2024
- Development of a New Positron Emission Tomography Imaging Radioligand Targeting RIPK1 in the Brain and Characterization in Alzheimer's DiseaseAdvanced Science, 2024
- Extracellular vesicles in skin health, diseases, and agingInterdisciplinary Medicine, 2024
- Synthesis and preclinical evaluation of 11C-labeled 7-Oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine radioligands for RIPK1 positron emission tomography imagingBioorganic Chemistry, 2024
- Development of NLRP3 PET Radiotracers for Alzheimer’s diseaseAlzheimer's & Dementia, 2023
- Alzheimer's disease and inflammatory biomarkers positively correlate in plasma in the UK‐ADRC cohortAlzheimer's & Dementia, 2023
- Structure‐Based Discovery of A Small Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) that Significantly Reduces Alzheimer's Disease NeuropathologyAdvanced Science, 2023
- Global estimates on the number of persons across the Alzheimer's disease continuumAlzheimer's & Dementia, 2022
- RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosisCell Reports, 2021
- Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteersPharmacology Research & Perspectives, 2017